Objective: People with psychosis have an elevated risk of depression and diabetes but no large-scale study has characterized their relationship. We aimed to assess this association and to evaluate possible explanatory factors. Methods: Analysis of cross-sectional data from a national sample of 1155 people with psychosis who gave a fasting blood sample and could be tested for diabetes mellitus. The association between current diabetes mellitus and current depression was estimated using logistic regression, adjusted for age, sex and current psychotropic medication. Results: A diagnosis of depression was significantly associated with diabetes (OR = 2.16, P = .048) and diabetes medication (OR = 2.50, P = .050) in people with schizophrenia but no other psychosis subtype. Adjustment for cognitive processing speed and current residence (especially psychiatric hospitalization) attenuated that association to nonsignificance. Diabetes and diabetes medication were not significantly associated with antidepressant or mood stabilizer medication. Conclusions: Clinicians should be aware that people with schizophrenia and diabetes have twice the rate of current depression, and that comorbid diabetes and depression is associated with cognitive impairment and hospitalization. Efforts to disentangle the causal pathways between diabetes, depression, and cognition in people with schizophrenia may be complicated by multiple indications in people with psychosis for the prescription of depression medication, and their lack of association with diabetes mellitus.
Introduction
Diabetes and depression are common and often chronic conditions. Their comorbidity is considered an emerging global public health challenge because of its consequences for long-term health and well-being. 1 Diabetes with depression is associated with worse self-care, worse adherence to treatment and worse quality of life, more complications of diabetes and a shorter life expectancy than diabetes without depression. 2 People with psychosis have an elevated risk of diabetes 3 and depression 4 but there are no large-scale studies examining depression in people with diabetes and psychosis, or its subtypes.
Depression symptom severity has been associated with diabetes-related disability in small clinical studies of schizophrenia, and depression has consequently been proposed as a tractable target for interventions to reduce disability. 5 Characterizing the prevalence of depression in people with diabetes and psychosis will inform diabetes treatment programs of the magnitude of the problem so they can monitor and treat emerging depression. Characterizing factors that attenuate the association between depression and diabetes in people with psychosis may identify important clinical and environmental targets to track in longitudinal investigations of causal pathways.
Depression and diabetes may be defined in multiple ways in research studies. Both may be assessed using internationally recognized diagnostic criteria 6, 7 such that everyone in a sample is tested for their presence. Alternately, each may be inferred based on current treatment alone. 8 This implies clinical detection which may, in turn, be correlated with severity or other factors associated with help seeking or screening. Only half of those with diabetes are detected clinically 9 and slightly fewer than half of those with diabetes who are also depressed are detected. 10 Different definitions of depression or diabetes may therefore differ in the pattern or strength of their correlates and this may influence perceptions of the presence, pattern or strength of comorbidity between depression and diabetes in people with psychosis.
The aims of this study were to test in a large national sample of adults with psychosis if (1) a research diagnosis of diabetes mellitus or treatment with diabetes drugs is associated with a research diagnosis of depression or treatment with antidepressant or mood stabilizing drugs, and (2) if any potentially explanatory factors could be identified such that observed associations were attenuated to nonsignificance.
Methods

Data Source and Study Population
The Australian National Survey of Psychosis is a cross-sectional study of people with psychosis ascertained from 7 mental health service sites in 5 Australian states, covering an estimated resident population of 1 464 923 people-about 10% of Australians in the target age range. The study sample comprised people who were resident in the catchment sites, aged 18-64 years and in contact with designated public mental health services (inpatient, outpatient, ambulatory, and community mental health) and nongovernment organizations that support people with mental illness. A 2-phase study design was used. In phase 1 (screening), individuals likely to meet diagnostic criteria for psychosis were identified from a census of people with psychosis done in March, 2010, and from a search of administrative records to identify individuals with psychosis who were in contact with public mental health services in the 11 months before census but not in the census month. In phase 2, identified individuals were randomly selected, stratified by site and age group, and interviewed between April and December, 2010. Details of the survey design, numbers of patients in each phase and a detailed description of study methods and measures are provided elsewhere. 11, 12 Data included in the present study are for those with an ICD-10 psychotic disorder (n = 1642) who also gave a fasting blood sample (n = 1155) which permitted testing for current diabetes: 591 (51%) with schizophrenia, 225 (19%) with bipolar disorder with psychotic features, 210 (18%) with schizoaffective disorder, 63 (5%) with depressive psychosis, and 66 (6%) with delusional disorders or other psychoses.
The research protocol for the study was approved by relevant institutional ethics committees and all participants gave written informed consent.
Measures
The Diagnostic Interview for Psychosis (DIP) 13 was used to diagnose psychotic disorders according to ICD-10. 14 The DIP depression symptom responses were used to approximate a diagnosis of current depressive episode according to ICD-10 criteria. Depression was rated according to whether depressed mood or anhedonia were present for at least 2 weeks-and based on the presence of 6 associated symptoms: fatigue; disturbed sleep; poor concentration or indecisiveness; increased or decreased appetite; agitation or slowed movement; and guilt or self-blame. Depression was rated as present if depressed mood or anhedonia were present for at least 2 weeks and the total depression symptom count was at least 4 (depression and/or anhedonia plus at least 2 of 6 contingent symptoms, 8 symptoms in all). This corresponds closely to ICD-10 depressive episode, with mild or greater severity.
A research diagnosis of current diabetes mellitus was diagnosed according to the American Diabetes Association 15 criteria as a fasting blood glucose reading of 7+ mmol/l or antidiabetic medication. Based on the prevalence in the Australian population, 9 we assume 85%-90% of participants with diabetes mellitus were type 2.
Antidiabetics, antipsychotics, mood stabilizers, antidepressants, and anxiolytics prescribed and dispensed for (at least) the entire month prior to survey were used to define current treatment in our analyses.
The following variables were extracted from the personal interview or cognitive assessments conducted during the survey and tested as possible explanatory variables for any observed association between diabetes and depression: duration of psychiatric illness, current negative symptoms of psychosis, current alcohol use, current tobacco use, current body mass index, perceived overall physical health, premorbid IQ (National Adult Reading TestRevised [NART-R]), current cognitive processing speed (Digit Symbol Coding Test [DSCT] ) from the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a domain that is impaired in those with diabetes, 16 education, employment, marital status, housing and global functioning (Multidimensional Scale of Independent Functioning [MSIF] ). These measures are described in detail elsewhere.
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Data Analysis
The cross-sectional association between depression and diabetes was estimated using logistic regression. The outcome variables were the research diagnosis of depressive episode and the 2 treatment-based indices-treatment with an antidepressant or treatment with a mood stabilizer. The predictor variables were a research diagnosis of current diabetes mellitus and the treatment-based index-treatment with an antidiabetic drug. These yielded 6 analyses comprising:
1. A research diagnosis of diabetes as a predictor of a research diagnosis of depression 2. Drug treatment for diabetes as a predictor of a research diagnosis of depression 3. A research diagnosis of diabetes as a predictor of antidepressant drug treatment 4. Drug treatment for diabetes as a predictor of antidepressant drug treatment 5. A research diagnosis of diabetes as a predictor of mood stabilizing drug treatment 6. Drug treatment for diabetes as a predictor of mood stabilizing drug treatment
Covariates Included in Analyses of Association
Estimates of association were adjusted for age in years and gender and then further adjusted for current antipsychotic and antianxiety medication. Adjusting for these medications ensures that antipsychotic or antianxiety medication prescribed to people who are also taking antidepressants or mood stabilizers are not explaining any association observed between diabetes or diabetes medication and antidepressants or mood stabilizers.
Analyses were conducted for all psychoses combined and for each psychosis subtype separately.
Covariates Tested as Potential Explanatory Factors for Any Observed Association
If the association between diabetes and depression was significant after adjustment for age, gender, current antipsychotic medication, and antianxiety medication, the following variables were tested for their ability to attenuate the association to nonsignificance: duration of psychiatric illness, number of negative symptoms, alcohol use, tobacco use, body mass index, perceived physical health, premorbid IQ, current cognitive processing speed, education, employment, marital status, housing, and global functioning. Sex differences and bias associated with giving a fasting blood sample were evaluated using the chi-squared test. All data analysis was conducted using SPSS Version 22.
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Results
Prevalence of Depression and Diabetes
The prevalence of current depression was 15.2% and was more common in women than men (18.0% vs 13.4%, P = .035) (table 1). Antidepressant or mood stabilizing medications were currently taken by 37.7% and 30.5% of the sample respectively, and more often by women than men (antidepressant: 45.5% of women vs 32.8% of men, P < .0001; mood stabilizer: 35.1% of women vs 27.6% of men, P = .007). Current diabetes mellitus was present in 12.1% of the sample. Insulin or an oral glucose lowering drug was currently taken by 7.9% of the sample.
Those taking an antidepressant or a mood stabilizer were more likely to give a fasting blood sample than those who were not taking an antidepressant (37.7% vs 31.6%, χ 2 = 5.43, P = .021) or a mood stabilizer (30.5% vs 24.6%, χ 2 = 5.69, P = .017). With respect to all the other variables examined in this report, those who gave a fasting blood sample were similar to those who did not (table 1) . There was a significantly increased odds of depression in association with diabetes medication in people with schizophrenia (OR = 2.57, P = .041 adjusted for age and sex; OR = 2.50, P = .05 adjusted for age, sex, antipsychotic and antianxiety medication, table 2). The prevalence of depression was 17.5% in people with schizophrenia who were taking diabetes medication and 8.9% in people with schizophrenia who were not taking diabetes medication (table 3) .
Association as a Function of Psychosis Subtypes
There was no significant association between depression and diabetes in people with any psychotic disorder subtype other than schizophrenia (table 2), but tests of heterogeneity between schizophrenia and other diagnostic subtypes were mostly nonsignificant. The association between depression and diabetes was not significantly different in people with schizophrenia compared to people with schizoaffective disorder (OR = 0.35, P = .10), bipolar disorder with psychotic features (OR = 0.36, P = .13), depressive psychosis (OR = 0.59, P = .56) or delusional disorder (OR = 4.51, P = .32). The association between depression and diabetes medication was significantly lower in people with schizoaffective disorder than in people with schizophrenia (OR = 0.16, P = .038) but was not significantly different in people with bipolar disorder with psychotic features (OR = 0.30, P = .13), depressive psychosis (OR = 0.67, P = .726) or delusional disorder (OR = 0.00, P = .99) than in people with schizophrenia.
The odds of depression in association with diabetes mellitus was OR = 2.05 (P = .062) in people with schizophrenia adjusted for age and gender, and OR = 2.26 (P = .044) adjusted for age, gender, antipsychotic, antianxiety, mood stabilizing, and antidepressant medication. The association between diabetes and depression in people with schizophrenia therefore could not be explained by psychotropic medication. Current antipsychotic medication was associated with a significantly lower odds of depression, and current antidepressant medication was associated with a significantly increased odds of depression, but neither attenuated the association between depression and diabetes.
Potential Confounders and Explanatory Factors
Adjustment for premorbid IQ, current cognitive processing speed and current housing (including psychiatric hospitalization) attenuated the odds of depression in those with diabetes. Including both current cognitive processing speed and housing (hospitalization) attenuated the association more than adjustment for either alone; adding premorbid IQ increased the association slightly. The odds of depression in association with diabetes after adjustment for age, gender, psychotropic medication, current cognitive processing speed and housing (hospitalization) was OR = 1.38 (P = .510) (table 4). Antipsychotic medication remained associated with a significantly lower odds of depression (adjusted OR = 0.20, P = .006) and antidepressant medication retained its association, with 2) . Being hospitalized/institutionalized were both associated with a significantly increased odds of depression (OR = 8.60, P = .002). Slow cognitive processing speed (a score < 1 SD below this sample's mean) was associated with substantial increased odds of depression, however this association narrowly escaped statistical significance (OR = 4.18, P = .058). Unlike adjustment for antipsychotic and antidepressant medication, the inclusion of either or both variables attenuated the association between depression and diabetes to nonsignificance.
Discussion
This is the first large scale examination of the cross-sectional relationship between depression and diabetes in people with psychotic disorders. There were 4 key findings, and several associated caveats for future studies that aim to elucidate and disentangle causal pathways. First, diabetes mellitus was associated with an increased rate of depression in people with schizophrenia. Compared to people with schizophrenia without diabetes, people with schizophrenia and current diabetes had approximately twice the rate of current depression. The prevalence of depression was slightly higher in those who were treated with diabetic medication. Drug treatment for diabetes implies its detection, and pathologic and functional changes in various target tissues may occur for several years before diabetes is clinically diagnosed. Detection is therefore associated with duration and severity of diabetes. 15 There may, therefore, be a modest effect of severity of diabetes on risk for depression, or vice-versa, or a diagnosis of diabetes based on clinical detection and drug treatment may be more reliable than a research diagnosis.
A 2-fold increased risk of depression in association with type 2 diabetes has been reported for the population. 2, 18 The prevalence of depression in those with schizophrenia and diabetes mellitus was similar to but slightly lower than the prevalence of depression in those with type 2 diabetes in the population (15.2% vs 19.1%, respectively), and the prevalence of depression in those with schizophrenia without diabetes mellitus was similar to but slightly lower than the prevalence of depression in those without type 2 diabetes in the population (8.8% vs 10.7%, respectively). 2 Housing circumstances, principally residing in a psychiatric hospital, could explain most of the association between depression and diabetes in people with schizophrenia. This factor is likely to be a marker for refractory disorder. The small numbers of such patients in this study precludes more detailed analysis but the invites further investigation in such samples.
Although narrowly escaping statistical significance, slow cognitive processing speed was a potential explanatory factor for the observed association between depression and diabetes. In a small community sample of people without psychosis people with type 2 diabetes and depression also had poorer attention/information processing speed than people with type 2 diabetes without depression. 19 The authors of that study suggested that depression negatively impacts cognitive performance, which may have implications for neural circuitry underlying cognitive and mood changes in diabetic patients. 19 Very slow processing speed is associated with severity of both psychosis and diabetes [20] [21] [22] and causal relationships may therefore be complex.
The relationship between diabetes mellitus and depression may not be uniform across psychotic disorders. Diabetes was associated with a significantly increased rate of depression in people with schizophrenia, a nonsignificantly increased rate in people with delusional disorder or depressive psychosis, and a nonsignificantly decreased rate in people with bipolar disorder with psychotic features or schizoaffective disorder. The association between diabetic medication and depression was significantly different in people with schizophrenia and schizoaffective disorder but larger samples are required to definitively address the possibility of heterogeneity across psychotic subtypes.
Third, people with schizophrenia and diabetes mellitus were not more likely to be treated with antidepressants than people with schizophrenia without diabetes mellitus. Like diabetes medication, antidepressant medication is often considered an index of severity of (depressive) illness but that may be only partly true in people with schizophrenia. Antidepressants are used to treat depression in people with schizophrenia but may also be prescribed to treat negative, positive, cognitive or antipsychotic-induced extrapyramidal symptoms. 23, 24 If the clinical indication for antidepressants is not recorded, and typically it isn't, then naturalistic treatment data, including national registry data, may be uninterpretable. This is an important methodological limitation that will confound efforts to disentangle causal pathways between diabetes and depression in people with schizophrenia and efforts to track the impact of interventions that are typically introduced at specified severity thresholds.
Finally, antipsychotic drug treatment was associated with a lower prevalence of depression in people with schizophrenia. Antipsychotic drugs were associated with a significantly lower odds of depression whereas antidepressants were associated with a significantly increased odds of depression, but neither explained the elevated rate of depression in people with diabetes and schizophrenia. It has been noted elsewhere that some of the atypical antipsychotics may have primary antidepressant effects. 4 Longitudinal studies that aim to test causal paths between diabetes and depression and their respective drug treatments should therefore take account of all psychotropic drug treatments and not just those that might be assumed to be specific for depression.
Limitations
Factors that moderate the relationship between depression and diabetes in psychosis may include variables not examined here. There were too few people with schizophrenia and diabetes mellitus in this study who were prescribed insulin (with or without oral antidiabetic drugs) vs oral antidiabetic drugs but not insulin to test if severity of diabetes moderated the observed association with depression. Gender is another possible moderating factor, and we encourage those with larger samples to consider both illness severity and gender in future studies. Finally, there was no adjustment for multiple testing in our analyses and some statistically significant findings may have occurred by chance. Replication is therefore required to determine if any of our reported results include false positives or false negatives.
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